



**ABSTRACT OF THE DISCLOSURE**


This invention comprises novel pharmaceutical carrier or excipient systems and oral  
 5 pharmaceutical formulations comprising as an active ingredient raloxifene, amoxifen,  
 droloxifene, arzoxifene, or CP 336156, or analogs thereof, or a compound of the formulae I or  
 II:



10 wherein Z is a moiety selected from the group of:



wherein: R<sub>1</sub> is selected from H, OH or the C<sub>1</sub>-C<sub>12</sub> esters alkyl ethers thereof, benzyloxy, or  
 halogen; or C<sub>1</sub>-C<sub>4</sub> halogenated ethers; R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, and R<sub>6</sub> are H, OH or C<sub>1</sub>-C<sub>12</sub> esters or  
 alkyl ethers thereof, halogens, or C<sub>1</sub>-C<sub>4</sub> halogenated ethers, cyano, C<sub>1</sub>-C<sub>6</sub> alkyl, or CF<sub>3</sub>, with  
 15 the proviso that, when R<sub>1</sub> is H, R<sub>2</sub> is not OH; Y is the moiety:



R<sub>7</sub> and R<sub>8</sub> are alkyl or concatenated together to form an optionally substituted, nitrogen-  
 containing ring; or a pharmaceutically acceptable salt thereof; and excipients chosen from  
 pharmaceutical fillers, glidants, lubricants, wetting agents and antioxidants.